Involvement of NRF2 Signaling in Doxorubicin Resistance of Cancer Stem Cell-Enriched Colonospheres.
10.4062/biomolther.2016.145
- Author:
In Geun RYOO
1
;
Geon KIM
;
Bo hyun CHOI
;
Sang Hwan LEE
;
Mi Kyoung KWAK
Author Information
1. Department of Pharmacy, Graduate School of The Catholic University of Korea, Republic of Korea. mkwak@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Cancer stem cells;
NRF2;
Colonospheres;
Drug efflux transporters;
Chemoresistance
- MeSH:
Breast Neoplasms;
Cell Death;
Doxorubicin*;
Drug Therapy;
Neoplastic Stem Cells;
NF-E2-Related Factor 2;
P-Glycoprotein;
Recurrence;
Transcription Factors;
Up-Regulation
- From:Biomolecules & Therapeutics
2016;24(5):482-488
- CountryRepublic of Korea
- Language:English
-
Abstract:
Cancer stem cells (CSCs) are a subset of tumor cells, which are characterized by resistance against chemotherapy and environmental stress, and are known to cause tumor relapse after therapy. A number of molecular mechanisms underlie the chemoresistance of CSCs, including high expression levels of drug efflux transporters. We investigated the role of the antioxidant transcription factor NF-E2-related factor 2 (NRF2) in chemoresistance development, using a CSC-enriched colonosphere system. HCT116 colonospheres were more resistant to doxorubicin-induced cell death and expressed higher levels of drug efflux transporters such as P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) compared to HCT116 monolayers. Notably, levels of NRF2 and expression of its target genes were substantially elevated in colonospheres, and these increases were linked to doxorubicin resistance. When NRF2 expression was silenced in colonospheres, Pgp and BCRP expression was downregulated, and doxorubicin resistance was diminished. Collectively, these results indicate that NRF2 activation contributes to chemoresistance acquisition in CSC-enriched colonospheres through the upregulation of drug efflux transporters.
